93 related articles for article (PubMed ID: 22027227)
1. [Burkitt lymphoma is a highly malign tumour with a doubling time of twenty-four hours].
Frølund UC; Nielsen SL; Hansen PB
Ugeskr Laeger; 2011 Oct; 173(43):2714-8. PubMed ID: 22027227
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
3. Burkitt lymphoma in children: the Israeli experience.
Eldar AH; Futerman B; Abrahami G; Attias D; Barak AB; Burstein Y; Dvir R; Gabriel H; Horovitz J; Kapelushnik J; Kaplinsky H; Miskin H; Sthoeger D; Toren A; Vilk-Revel S; Weintraub M; Yaniv I; Linn S; Arush MB
J Pediatr Hematol Oncol; 2009 Jun; 31(6):428-36. PubMed ID: 19648792
[TBL] [Abstract][Full Text] [Related]
4. Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
Baleydier F; Pondarre C; Pages MP; Mialou V; Kebaili K; Pracros JP; Bertrand Y
J Pediatr Hematol Oncol; 2008 Dec; 30(12):972-5. PubMed ID: 19131795
[TBL] [Abstract][Full Text] [Related]
5. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
6. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
Todeschini G; Bonifacio M; Tecchio C; Balter R; Carli G; Stefani PM; Adami F; Zamò A; Dei Tos AP; Marino F; Gherlinzoni F; Marradi P; Semenzato G; Pizzolo G
Am J Hematol; 2012 Jan; 87(1):22-5. PubMed ID: 22086870
[TBL] [Abstract][Full Text] [Related]
7. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials.
Seidemann K; Meyer U; Jansen P; Yakisan E; Rieske K; Führer M; Kremens B; Schrappe M; Reiter A
Klin Padiatr; 1998; 210(4):279-84. PubMed ID: 9743966
[TBL] [Abstract][Full Text] [Related]
8. [Diffuse large B-cell lymphoma with strongly positive MIB-1 stain and clinical features resembling Burkitt lymphoma].
Wakimoto N; Misumi M; Maeda T; Shimada T; Wakao D; Sato Y; Takahashi N; Sugahara Y; Yoshida K; Yagasaki F; Nakamura Y; Kawai N; Matsuda A; Kayano H; Jinnai I; Bessho M
Rinsho Ketsueki; 2005 Jun; 46(6):458-62. PubMed ID: 16447728
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
Choi KA; Lee JE; Kim YG; Kim DJ; Kim K; Ko YH; Oh HY; Kim WS; Huh W
Ann Hematol; 2009 Jul; 88(7):639-45. PubMed ID: 19030857
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. Is intestinal diffuse large b cell lymphoma a relatively benign disease?
Daum S; Thiel E; Zeitz M
Leuk Res; 2007 Mar; 31(3):287-9. PubMed ID: 17010434
[No Abstract] [Full Text] [Related]
12. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
13. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
Tauro S; Cochrane L; Lauritzsen GF; Baker L; Delabie J; Roberts C; Mahendra P; Holte H
Am J Hematol; 2010 Apr; 85(4):261-3. PubMed ID: 20201088
[TBL] [Abstract][Full Text] [Related]
14. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in B cell acute lymphoblastic leukemia (Burkitt leukemia) therapy in childhood.
Baruchel A; Schaison G
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):106-8. PubMed ID: 8511033
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma.
Lerede T; Bassan R; Rossi A; Di Bona E; Rossi G; Pogliani EM; Motta T; Torri V; Buelli M; Comotti B; Viero P; Rambaldi A; Cortelazzo S; Rodeghiero F; Barbui T
Haematologica; 1996; 81(5):442-9. PubMed ID: 8952158
[TBL] [Abstract][Full Text] [Related]
17. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic progress in acute lymphoblastic leukemias and stage IV Burkitt-type lymphomas in children].
Leverger G; Patte C
Bull Acad Natl Med; 2003; 187(4):743-55; discussion 755-7. PubMed ID: 14556479
[TBL] [Abstract][Full Text] [Related]
19. Burkitt lymphoma involving the clivus.
Aronson PL; Reilly A; Paessler M; Kersun LS
J Pediatr Hematol Oncol; 2008 Apr; 30(4):320-1. PubMed ID: 18391704
[TBL] [Abstract][Full Text] [Related]
20. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
